Kathy Rivet Amico

Kathy Rivet Amico

Auto-generated profile, based on publicly available information

Kathy Rivet Amico

University of Michigan

Research Focus & Metrics

Academic Career Length

44Years (1983-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 December 2010 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
RGRobert M. Grant
Robert M. Grant
JLJavier R. Lama
Javier R. Lama
PAPeter L. Anderson
Peter L. Anderson
VMVanessa McMahan
Vanessa McMahan
ALAlbert Y. Liu
Albert Y. Liu
DGDavid V. Glidden
David V. Glidden
Antiretroviral chemoprophylaxis before exposure is a promising approach for the prevention of human immunodeficiency virus (HIV) acquisition. We randomly assigned 2499 HIV-seronegative men or transgender women who have sex with men to receive a combination of two oral antiretroviral drugs, emtricitabine and tenofovir disoproxil fumarate (FTC–TDF), or placebo once daily. All subjects received HIV testing, risk-reduction counseling, condoms, and management of sexually transmitted infections. The study subjects were followed for 3324 person-years (median, 1.2 years; maximum, 2.8 years). Of these subjects, 10 were found to have been infected with HIV at enrollment, and 100 became infected during follow-up (36 in the FTC–TDF group and 64 in the placebo group), indicating a 44% reduction in the incidence of HIV (95% confidence interval, 15 to 63; P=0.005). In the FTC–TDF group, the study drug was detected in 22 of 43 of seronegative subjects (51%) and in 3 of 34 HIV-infected subjects (9%) (P<0.001). Nausea was reported more frequently during the first 4 weeks in the FTC–TDF group than in the placebo group (P<0.001). The two groups had similar rates of serious adverse events (P=0.57). Oral FTC–TDF provided protection against the acquisition of HIV infection among the subjects. Detectable blood levels strongly correlated with the prophylactic effect. (Funded by the National Institutes of Health and the Bill and Melinda Gates Foundation; ClinicalTrials.gov number, NCT00458393.)

1 September 2014 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
RGRobert M Grant
Robert M Grant
PAPeter L Anderson
Peter L Anderson
VMVanessa McMahan
Vanessa McMahan
ALAlbert Liu
Albert Liu
KAK Rivet Amico
K Rivet Amico
DGDavid V Glidden
David V Glidden

3 March 2013 in AIDS and Behavior
Verified
Journal Article
Closed access
PDF file
VEValerie A. Earnshaw
Valerie A. Earnshaw
LSLaramie R. Smith
Laramie R. Smith
SCStephenie R. Chaudoir
Stephenie R. Chaudoir
KAK. Rivet Amico
K. Rivet Amico
MCMichael M. Copenhaver
Michael M. Copenhaver

1 July 2006 in Health Psychology
Verified
Journal Article
Closed access
JFJeffrey D. Fisher
Jeffrey D. Fisher
WFWilliam A. Fisher
William A. Fisher
KAK. Rivet Amico
K. Rivet Amico
JHJennifer J. Harman
Jennifer J. Harman
HIV-positive persons who do not maintain consistently high levels of adherence to often complex and toxic highly active antiretroviral therapy (HAART) regimens may experience therapeutic failure and deterioration of health status and may develop multidrug-resistant HIV that can be transmitted to uninfected others. The current analysis conceptualizes social and psychological determinants of adherence to HAART among HIV-positive individuals. The authors propose an information-motivation-behavioral skills (IMB) model of HAART adherence that assumes that adherence-related information, motivation, and behavioral skills are fundamental determinants of adherence to HAART. According to the model, adherence-related information and motivation work through adherence-related behavioral skills to affect adherence to HAART. Empirical support for the IMB model of adherence is presented, and its application in adherence-promotion intervention efforts is discussed.

1 January 2016 in JAMA Internal Medicine
Verified
Journal Article
Open access
PDF file
ALAlbert Y. Liu
Albert Y. Liu
SCStephanie E. Cohen
Stephanie E. Cohen
EVEric Vittinghoff
Eric Vittinghoff
PAPeter L. Anderson
Peter L. Anderson
SDSusanne Doblecki-Lewis
Susanne Doblecki-Lewis
MKMichael A. Kolber
Michael A. Kolber
In 2010, the Pre-exposure Prophylaxis Initiative (iPrEx) trial of preexposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) infection used a combination of daily oral tenofovir disoproxil fumarate and emtricitabine to demonstrate an overall 44% reduction in HIV acquisition among men who have sex with men (MSM) and transgender women receiving PrEP and greater than 90% efficacy among those with detectable drug levels in blood samples.1 After 2 additional randomized clinical trials demonstrated safety and efficacy,2,3 this PrEP formulation was approved in the United States for the prevention of sexually acquired HIV infection in 2012.4 Two recent studies of daily or intermittent PrEP among MSM5,6 confirmed high PrEP efficacy.

5 June 2012 in Annals of Internal Medicine
Verified
Journal Article
Open access
MTMelanie A. Thompson
Melanie A. Thompson
MMMichael J. Mugavero
Michael J. Mugavero
KAK. Rivet Amico
K. Rivet Amico
VCVictoria A. Cargill
Victoria A. Cargill
LCLarry W. Chang
Larry W. Chang
JNJean B. Nachega
Jean B. Nachega
The International Association of Physicians in AIDS Care convened a panel to develop evidence-based recommendations to optimize entry into and retention in care and antiretroviral therapy (ART) adh... Description: After HIV diagnosis, timely entry into HIV medical care and retention in that care are essential to the provision of effective antiretroviral therapy (ART). Adherence to ART is among t...